U.S. markets closed

Nkarta, Inc. (NKTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.47+1.95 (+7.35%)
At close: 4:00PM EDT
28.47 0.00 (0.00%)
After hours: 05:37PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Diamond Bottom

Diamond Bottom

Previous Close26.52
Open27.02
Bid27.02 x 1100
Ask29.90 x 800
Day's Range26.59 - 28.50
52 Week Range22.46 - 79.16
Volume145,969
Avg. Volume228,154
Market Cap934.459M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 18, 2021 - Aug 23, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est77.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Nkarta to Present at Upcoming Investor Conference
    GlobeNewswire

    Nkarta to Present at Upcoming Investor Conference

    SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference: Raymond James Human Health Innovation ConferenceJune 21, 20213:20 p.m. ET - fireside chat presentation The live webcast of the presentation will be available on the Investors section of Nkarta’s website, www.nkartatx.com. A replay of

  • Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term
    GlobeNewswire

    Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term

    SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Chief Executive Officer Paul Hastings has been elected as the Chair of the Biotechnology Innovation Organization (BIO) Board of Directors for the 2021-2022 term. “Paul is a true biotech pioneer with an incredible journey first as a patient, then as a patient advocate, a biotech innova

  • Motley Fool

    How Much Will the Nkarta Deal Help CRISPR Therapeutics?

    CRISPR Therapeutics (NASDAQ: CRSP) and Nkarta (NASDAQ: NKTX) recently formed a pact to use CRISPR's gene editing tool to create natural killer (NK) cell therapies. In this video from Motley Fool Live, recorded on May 10, Fool.